- Asmar M, Simonsen L, Asmar A, et al. Insulin plays a permissive role for the vasoactive effect of GIP regulating adipose tissue metabolism in humans. J Clin Endocrinol Metab 2016;101(8):3155–62.
- Getty-Kaushik L, Song DH, Boylan MO, et al. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity (Silver Spring) 2006;14(7):1124–31.
- Newgard CB. Metabolomics and metabolic diseases: where do we stand? Cell Metab 2017;25(1):43–56.
- Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17(4):448–53.
- Flores-Guerrero JL, Osté MCJ, Kieneker LM, et al. Plasma branched-chain amino acids and risk of incident type 2 diabetes: results from the PREVEND prospective cohort study. J Clin Med 2018;7(12):513.
- Lotta LA, Scott RA, Sharp SJ, et al. Genetic predisposition to an impaired metabolism of the branched-chain amino acids and risk of type 2 diabetes: a mendelian randomisation analysis. PLoS Med 2016;13(11):e1002179.
Tirzepatide: post hoc assessment of metabolome changes
Key messages
- Several metabolite clusters have emerged that associate with obesity, insulin resistance, and risk for future development of diabetes.
- In this Phase 2 post hoc analysis, tirzepatide had specific and selective effects on three sets of metabolites that are associated with glycemic phenotypes.
- In addition to lowering body weight and improving glycemic control, tirzepatide can modify a set of metabolic factors previously shown to be associated with diabetes risk and insulin resistance.
